Work

Etctn 10388: A phase I trial of triapine and lutetium Lu 177 dotatate in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps4660

Authors: Aman Chauhan, Charles Kunos, Riham El Khouli, Jill Kolesar, Heidi Weiss, William Edgar Carson, Mark B Evers, Mark S. Kidd, Jan Hendrik Beumer, Susanne M. Arnold, Elise C. Kohn, Lowell Brian Anthony

Institutions: University of Kentucky, Summa Health System, Markey Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Yale University, UPMC Hillman Cancer Center, NSABP Foundation, National Cancer Institute, Center for Cancer Research

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3030932022

Cites:

Cited by: 4

Related to: 10